This report presents a patient with a sporadic, cutaneous angiosarcoma harboring high-level amplifications of members of the VEGFR family, specifically VEGFR2 (KDR; 8x) and VEGFR3 (FLT4; 16x). In response to pazopanib, an inhibitor of both VEGFR2 and VEGFR3, the patient experienced disease control for 6 month.